Proteasomal regulation of pulmonary fibrosis

Proceedings of the American Thoracic Society

Volumn 7, Issue 1, 2010, Pages 77-83

  Weiss, Curtis H ^a   Budinger, G R Scott ^a   Mutlu, Gökhan M ^a   Jain, Manu ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Acute respiratory distress syndrome; Smad; Transforming growth factor 1; Ubiquitination

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CARFILZOMIB; DEXAMETHASONE; EPOXOMICIN; IMATINIB; LACTACYSTIN BETA LACTONE; N BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLALANYLLEUCINAL; PROTEASOME; PROTEASOME INHIBITOR; ROSIGLITAZONE; SALINOSPORAMIDE A; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; BORONIC ACID DERIVATIVE; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; SMAD PROTEIN; UBIQUITIN;

ABDOMINAL PAIN; ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ANOREXIA; BONE PAIN; CONSTIPATION; COUGHING; DIARRHEA; DYSPNEA; FATIGUE; FEVER; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; INSOMNIA; LIMB PAIN; LUNG FIBROSIS; LUNG TOXICITY; MANTLE CELL LYMPHOMA; MORTALITY; MULTIPLE MYELOMA; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; NONHUMAN; PARESTHESIA; PERIPHERAL NEUROPATHY; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RASH; RESPIRATORY DISTRESS; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; VOMITING; ANIMAL; CLINICAL TRIAL; DRUG ANTAGONISM; METABOLISM; PATHOLOGY;

ANIMALS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; HUMANS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PULMONARY FIBROSIS; PYRAZINES; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1; UBIQUITIN;

EID: 77953256302     PISSN: 15463222     EISSN: 19435665     Source Type: Journal    
DOI: 10.1513/pats.200906-055JS     Document Type: Review

References (74)

1. Martin C, Papazian L, Payan MJ, Saux P, Gouin F. Pulmonary fibrosis correlates with outcome in adult respiratory distress syndrome: a study in mechanically ventilated patients. Chest 1995;107:196-200. (see comments).
2. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114:1308-1316. (Pubitemid 40385302)
3. Bonniaud P, Margetts PJ, Ask K, Flanders K, Gauldie J, Kolb M. TGFbeta and Smad3 signaling link inflammation to chronic fibrogenesis. J Immunol 2005;175:5390-5395. (Pubitemid 41456425)
4. Tomashefski JF Jr. Pulmonary pathology of acute respiratory distress syndrome. Clin Chest Med 2000;21:435-466.
5. Hardie WD, Glasser SW, Hagood JS. Emerging concepts in the pathogenesis of lung fibrosis. Am J Pathol 2009;175:3-16.
6. Budinger GR, Mutlu GM, Eisenbart J, Fuller AC, Bellmeyer AA, Baker CM, Wilson M, Ridge K, Barrett TA, Lee VY, et al. Proapoptotic Bid is required for pulmonary fibrosis. Proc Natl Acad Sci USA 2006;103:4604-4609.
7. Sheppard D. Transforming growth factor β: a central modulator of pulmonary and airway inflammation and fibrosis. Proc Am Thorac Soc 2006;3:413-417.
8. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-151. (Pubitemid 32096342)
9. Sato Y, Tsuboi R, Lyons R, Moses H, Rifkin DB. Characterization of the activation of latent TGF-beta by co-cultures of endothelial cells and pericytes or smooth muscle cells: a self-regulating system. J Cell Biol 1990;111:757-763.
10. Barcellos-Hoff MH, Dix TA. Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol 1996;10:1077-1083. (Pubitemid 26299216)
11. Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest 1994;93:892-899.
12. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998;93:1159-1170. (Pubitemid 28307421)
13. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, et al. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999;96:319-328. (Pubitemid 29077586)
14. Bonniaud P, Margetts PJ, Kolb M, Schroeder JA, Kapoun AM, Damm D, Murphy A, Chakravarty S, Dugar S, Higgins L, et al. Progressive transforming growth factor β1 - induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor. Am J Respir Crit Care Med 2005;171:889-898. (Pubitemid 40562720)
15. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003;425:577-584. (Pubitemid 37280136)
16. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 2000;6:1365-1375. (Pubitemid 32045929)
17. Ghosh AK, Bhattacharyya S, Lakos G, Chen SJ, Mori Y, Varga J. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator - activated receptor gamma. Arthritis Rheum 2004;50:1305-1318. (Pubitemid 38480842)
18. Deheuninck J, Luo K. Ski and SnoN, potent negative regulators of TGF-beta signaling. Cell Res 2009;19:47-57.
19. Varga J, Jimenez SA. Stimulation of normal human fibroblast collagen production and processing by transforming growth factor - beta. Biochem Biophys Res Commun 1986;138:974-980. (Pubitemid 16013227)
20. Zhang K, Rekhter MD, Gordon D, Phan SH. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis: a combined immunohistochemical and in situ hybridization study. Am J Pathol 1994;145:114-125. (Pubitemid 24217490)
21. Scotton CJ, Chambers RC. Molecular targets in pulmonary fibrosis: the myofibroblast in focus. Chest 2007;132:1311-1321.
22. Kim KK, Kugler MC, Wolters PJ, Robillard L, Galvez MG, Brumwell AN, Sheppard D, Chapman HA. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci USA 2006; 103:13180-13185. (Pubitemid 44338936)
23. Puthawala K, Hadjiangelis N, Jacoby SC, Bayongan E, Zhao Z, Yang Z, Devitt ML, Horan GS, Weinreb PH, Lukashev ME, et al. Inhibition of integrin αvβ6, an activator of latent transforming growth factor - β, prevents radiation-induced lung fibrosis. Am J Respir Crit Care Med 2008;177:82-90.
24. Schmierer B, Hill CS. TGFbeta-Smad signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007;8:970-982. (Pubitemid 350174642)
25. Kapoun AM, Gaspar NJ, Wang Y, Damm D, Liu YW, O'Young G, Quon D, Lam A, Munson K, Tran TT, et al. Transforming growth factor-beta receptor type 1 (TGFβRI) kinase activity but not p38 activation is required for TGFbRI-induced myofibroblast differentiation and profibrotic gene expression. Mol Pharmacol 2006;70:518-531. (Pubitemid 44092313)
26. Ramirez AM, Shen Z, Ritzenthaler JD, Roman J. Myofibroblast trans-differentiation in obliterative bronchiolitis: TGF-beta signaling through Smad3-dependent and -independent pathways. Am J Transplant 2006;6:2080-2088. (Pubitemid 44199542)
27. Hu Y, Peng J, Feng D, Chu L, Li X, Jin Z, Lin Z, Zeng Q. Role of extracellular signal-regulated kinase, p38 kinase, and activator protein - 1 in transforming growth factor - beta1 - induced alpha smooth muscle actin expression in human fetal lung fibroblasts in vitro. Lung 2006;184:33-42.
28. Smith PC, Caceres M, Martinez J. Induction of the myofibroblastic phenotype in human gingival fibroblasts by transforming growth factor-beta1: role of Rhoa-rock and c-Jun N-terminal kinase signaling pathways. J Periodontal Res 2006;41:418-425. (Pubitemid 44337257)
29. Hashimoto S, Gon Y, Takeshita I, Matsumoto K, Maruoka S, Horie T. Transforming growth factor - b1 induces phenotypic modulation of human lung fibroblasts to myofibroblast through a c-Jun - NH2-terminal kinase - dependent pathway. Am J Respir Crit Care Med 2001;163:152-157. (Pubitemid 32095266)
30. Aono Y, Nishioka Y, Inayama M, Ugai M, Kishi J, Uehara H, Izumi K, Sone S. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005;171:1279-1285. (Pubitemid 40740736)
31. Vittal R, Zhang H, Han MK, Moore BB, Horowitz JC, Thannickal VJ. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases. J Pharmacol Exp Ther 2007;321:35-44. (Pubitemid 46456971)
32. Chen H, He YW, Liu WQ, Zhang JH. Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum. World J Gastroenterol 2008;14:2905-2911.
33. Burgess HA, Daugherty LE, Thatcher TH, Lakatos HF, Ray DM, Redonnet M, Phipps RP, Sime PJ. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005;288:L1146-L1153. (Pubitemid 40695441)
34. Milam JE, Keshamouni VG, Phan SH, Hu B, Gangireddy SR, Hogaboam CM, Standiford TJ, Thannickal VJ, Reddy RC. PPARgamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008;294:L891-L901.
35. Hauser S, Adelmant G, Sarraf P, Wright HM, Mueller E, Spiegelman BM. Degradation of the peroxisome proliferator - activated receptor gamma is linked to ligand-dependent activation. J Biol Chem 2000;275:18527-18533. (Pubitemid 30414814)
36. Ciehanover A, Hod Y, Hershko A. A heat-stable polypeptide component of an ATP-dependent proteolytic system from reticulocytes. Biochem Biophys Res Commun 1978;81:1100-1105. (Pubitemid 8331462)
37. Ciechanover A, Iwai K. The ubiquitin system: from basic mechanisms to the patient bed. IUBMB Life 2004;56:193-201. (Pubitemid 38828747)
38. Reinstein E, Ciechanover A. Narrative review: protein degradation and human diseases: the ubiquitin connection. Ann Intern Med 2006;145:676-684. (Pubitemid 46768844)
39. Glickman MH, Adir N. The proteasome and the delicate balance between destruction and rescue. PLoS Biol 2004;2:E13.
40. Sixt SU, Dahlmann B. Extracellular, circulating proteasomes and ubiquitin - incidence and relevance. Biochim Biophys Acta 2008;1782:817-823.
41. Sixt SU, Beiderlinden M, Jennissen HP, Peters J. Extracellular proteasome in the human alveolar space: a new housekeeping enzyme? Am J Physiol Lung Cell Mol Physiol 2007;292:L1280-L1288.
42. Sixt SU, Adamzik M, Spyrka D, Saul B, Hakenbeck J, Wohlschlaeger J, Costabel U, Kloss A, Giesebrecht J, Dahlmann B, et al. Alveolar extracellular 20S proteasome in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 2009;179:1098-1106.
43. Egerer K, Kuckelkorn U, Rudolph PE, Ruckert JC, Dorner T, Burmester GR, Kloetzel PM, Feist E. Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol 2002;29:2045-2052.
44. Elliott PJ, Zollner TM, Boehncke WH. Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 2003;81:235-245. (Pubitemid 36578922)
45. Borissenko L, Groll M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev 2007;107:687-717. (Pubitemid 46502369)
46. Groll M, Huber R, Moroder L. The persisting challenge of selective and specific proteasome inhibition. J Pept Sci 2009;15:58-66.
47. Inoue Y, Imamura T. Regulation of TGF-beta family signaling by E3 ubiquitin ligases. Cancer Sci 2008;99:2107-2112.
48. Levy L, Howell M, Das D, Harkin S, Episkopou V, Hill CS. Arkadia activates Smad3/Smad4-dependent transcription by triggering signal-induced SnoN degradation. Mol Cell Biol 2007;27:6068-6083. (Pubitemid 47326695)
49. Nagano Y, Mavrakis KJ, Lee KL, Fujii T, Koinuma D, Sase H, Yuki K, Isogaya K, Saitoh M, Imamura T, et al. Arkadia induces degradation of SnoN and c-Ski to enhance transforming growth factor-beta signaling. J Biol Chem 2007;282:20492-20501. (Pubitemid 47100041)
50. Tashiro K, Tamada S, Kuwabara N, Komiya T, Takekida K, Asai T, Iwao H, Sugimura K, Matsumura Y, Takaoka M, et al. Attenuation of renal fibrosis by proteasome inhibition in rat obstructive nephropathy: possible role of nuclear factor kappaB. Int J Mol Med 2003;12:587-592.
51. Meiners S, Hocher B, Weller A, Laule M, Stangl V, Guenther C, Godes M, Mrozikiewicz A, Baumann G, Stangl K. Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension 2004;44:471-477. (Pubitemid 39281498)
52. Pan X, Hussain FN, Iqbal J, Feuerman MH, Hussain MM. Inhibiting proteasomal degradation of microsomal triglyceride transfer protein prevents CCL4-induced steatosis. J Biol Chem 2007;282:17078-17089. (Pubitemid 47093224)
53. Anan A, Baskin-Bey ES, Bronk SF, Werneburg NW, Shah VH, Gores GJ. Proteasome inhibition induces hepatic stellate cell apoptosis. Hepatology 2006;43:335-344.
54. Wagner-Ballon O, Pisani DF, Gastinne T, Tulliez M, Chaligne R, Lacout C, Aurade F, Villeval JL, Gonin P, Vainchenker W, et al. Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. Blood 2007;110:345-353. (Pubitemid 47026853)
55. Fineschi S, Bongiovanni M, Donati Y, Djaafar S, Naso F, Goffin L, Argiroffo CB, Pache JC, Dayer JM, Ferrari-Lacraz S, et al. In vivo investigations on anti-fibrotic potential of proteasome inhibition in lung and skin fibrosis. Am J Respir Cell Mol Biol 2008;39:458-465.
56. Fineschi S, Reith W, Guerne PA, Dayer JM, Chizzolini C. Proteasome blockade exerts an antifibrotic activity by coordinately down-regulating type I collagen and tissue inhibitor of metalloproteinase - 1 and upregulating metalloproteinase-1 production in human dermal fibroblasts. FASEB J 2006;20:562-564. (Pubitemid 46671250)
57. Ghosh AK, Bhattacharyya S, Wei J, Kim S, Barak Y, Mori Y, Varga J. Peroxisome proliferator-activated receptor-{gamma} abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J 2009;23:2968-2977.
58. Horowitz JC, Lee DY, Waghray M, Keshamouni VG, Thomas PE, Zhang H, Cui Z, Thannickal VJ. Activation of the pro-survival phosphatidylinositol 3-kinase/Akt pathway by transforming growth factor - beta1 in mesenchymal cells is mediated by p38 MAPKdependent induction of an autocrine growth factor. J Biol Chem 2004;279:1359-1367. (Pubitemid 38082662)
59. Horowitz JC, Cui Z, Moore TA, Meier TR, Reddy RC, Toews GB, Standiford TJ, Thannickal VJ. Constitutive activation of prosurvival signaling in alveolar mesenchymal cells isolated from patients with nonresolving acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2006;290:L415-L425. (Pubitemid 43725086)
60. Lappi-Blanco E, Soini Y, Paakko P. Apoptotic activity is increased in the newly formed fibromyxoid connective tissue in bronchiolitis obliterans organizing pneumonia. Lung 1999;177:367-376.
61. Tan R, He W, Lin X, Kiss LP, Liu Y. Smad ubiquitination regulatory factor - 2 in the fibrotic kidney: regulation, target specificity, and functional implication. Am J Physiol Renal Physiol 2008;294:F1076-F1083.
62. Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF. New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings. Lancet Oncol 2008;9:1157-1165.
63. Rameshwar P, Narayanan R, Qian J, Denny TN, Colon C, Gascon P. NFkappa B as a central mediator in the induction of TGF-beta in monocytes from patients with idiopathic myelofibrosis: an inflammatory response beyond the realm of homeostasis. J Immunol 2000;165:2271-2277. (Pubitemid 30643178)
64. Bitzer M, von Gersdorff G, Liang D, Dominguez-Rosales A, Beg AA, Rojkind M, Bottinger EP. A mechanism of suppression of TGF-beta/Smad signaling by NF-kappa B/RelA. Genes Dev 2000;14:187-197. (Pubitemid 30070984)
65. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
66. Mateos-Mazon J, Perez-Simon JA, Lopez O, Hernandez E, Etxebarria J, San Miguel JF. Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation. Haematologica 2007;92:1295-1296. (Pubitemid 350144204)
67. El-Cheikh J, Michallet M, Nagler A, de Lavallade H, Nicolini FE, Shimoni A, Faucher C, Sobh M, Revesz D, Hardan I, et al. High response rate and improved graft-versus-host disease following bortezomib as salvage therapy after reduced intensity conditioning allogeneic stem cell transplantation for multiple myeloma. Haematologica 2008;93:455-458. (Pubitemid 351398650)
68. Banovic T, MacDonald KP, Morris ES, Rowe V, Kuns R, Don A, Kelly J, Ledbetter S, Clouston AD, Hill GR. TGF-beta in allogeneic stem cell transplantation: friend or foe? Blood 2005;106:2206-2214.
69. Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M, Narimatsu H, Fujii T, Kawabata M, Taniguchi S, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006;107:3492-3494.
70. Ogawa Y, Tobinai K, Ogura M, Ando K, Tsuchiya T, Kobayashi Y, Watanabe T, Maruyama D, Morishima Y, Kagami Y, et al. Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. Cancer Sci 2008;99:140-144. (Pubitemid 350239042)
71. Narimatsu H, Hori A, Matsumura T, Kodama Y, Takita M, Kishi Y, Hamaki T, Yuji K, Tanaka Y, Komatsu T, et al. Cooperative relationship between pharmaceutical companies, academia, and media explains sharp decrease in frequency of pulmonary complications after bortezomib in Japan. J Clin Oncol 2008;26:5820-5823.
72. Ohri A, Arena FP. Severe pulmonary complications in African American patient after bortezomib therapy. Am J Ther 2006;13:553-555. (Pubitemid 44813688)
73. Boyer JE, Batra RB, Ascensao JL, Schechter GP. Severe pulmonary complication after bortezomib treatment for multiple myeloma. Blood 2006;108:1113. (Pubitemid 44154659)
74. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617. (Pubitemid 36741588)